Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

FuturHealth vs MultiMedRx

FuturHealth
Graded #220

Higher grade

vs+7.999999999999993
MultiMedRx
Graded #394

Lower grade

The verdict

FuturHealth takes it — 65.6/100 to 57.6/100.

FuturHealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FuturHealth Inc. is a San Diego-based telehealth weight management brand offering brand-name Ozempic, Wegovy (injection AND oral pill), Mounjaro, Zepbound, and Foundayo (orforglipron oral pill, added

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueFuturHealth +15
60
45
Dose & formulationFuturHealth +28
81
53
Clinical oversightMultiMedRx +12
67
79
Labs & monitoringFuturHealth +8
61
53
FulfillmentMultiMedRx +5
62
67
Contract termsFuturHealth +6
55
49
FuturHealth · left barMultiMedRx · right bar

The numbers

MetricFuturHealthMultiMedRx
WeighScore65.6/10057.6/100
GradeCC
Scorecard rank#220#394
Semaglutide$199/mo (compounded)Not disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesYes
Oral / sublingualYesInjection only
FuturHealth

Graded #220 · C

Strengths

  • LegitScript Certified and HITRUST Certified
  • Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
  • Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
  • Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths

Where it loses points

  • Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
  • BBB complaints describe recurring charges without medication received — confirm cancellation flow first
  • Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
  • Pricing not shown until after the qualification questionnaire or portal login
  • Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber
MultiMedRx

Graded #394 · C

Strengths

  • Legal entity disclosed (MMRX MultiMedRx LLC) — uncommon transparency
  • Two physical addresses listed: Newport Beach, CA and Reno, NV
  • LegitScript seal present
  • Features brand-name GLP-1s (Ozempic, Wegovy, Zepbound) — rare in a mostly compounded-only field
  • Broader cardiometabolic menu (metformin, testosterone, HRT) alongside GLP-1

Where it loses points

  • No Mounjaro or Foundayo in the brand-name lineup (only Ozempic, Wegovy, Zepbound)
  • Monthly GLP-1 pricing isn't published — gated behind the consultation
  • $100 consultation fee adds friction; many peers bundle it into the medication price
  • Per-state availability not listed; only CA and NV offices disclosed
  • Whether compounded GLP-1 is offered isn't clear — verify during intake

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard